17. November 2009 07:35
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
[More]
a1f7ad01-51ab-49e4-b5f8-42264963fa09|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Angiogenesis, Cancer, Cell, Cell Proliferation, Hepatitis B, Hepatocellular Carcinoma, Kidney Cancer, Kinase Inhibitor, Liver Cancer, Multiple Sclerosis, Nexavar, Oncology, Sorafenib
16. November 2009 10:47
Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.
[More]
f3aba2b0-84f6-4e58-a90b-5057d67253a0|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Biotechnology, Bone, Bone Marrow, Cancer, Cell, Cell Proliferation, Hematology, Insulin, Kinase Inhibitor, Oncology, Rapamycin
16. November 2009 08:53
Oncothyreon Inc. today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.
[More]
16. November 2009 07:37
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2009.
[More]
11. November 2009 01:00
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
[More]
034f3dca-cb4c-46c0-a8c9-7be652652d7a|0|.0
Posted in: Women's Health News | Pharmaceutical News
Tags: Breast Cancer, Cancer, Cell, Chemotherapy, Chronic Myeloid Leukemia, Education, Gene Expression, Hematology, Kinase Inhibitor, Leukemia, Myeloid Leukemia, Oncology, Ovarian Cancer, Sprycel
9. November 2009 09:17
CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.
[More]
501b5920-8b6e-4819-adb5-ce67f9a54d60|0|.0
Posted in: Business / Finance
Tags: Arsenic, Brain, Breast Cancer, Cancer, Cell, Chromosome, Chronic Myeloid Leukemia, Doxorubicin, Gleevec, Investment, Kinase Inhibitor, Leukemia, Myeloid Leukemia, Oncology, Ovarian Cancer, Pancreatic Cancer, Retinoic Acid, Stroke
5. November 2009 08:19
ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.
[More]
5. November 2009 07:59
ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.
[More]
09ef16a1-b516-4e5f-bf29-b4007205e95b|0|.0
Posted in: Business / Finance
Tags: Adenosine, Biotechnology, Cancer, Cell, DNA, Erlotinib, Fibroblast, Gemcitabine, Hepatocellular Carcinoma, Kinase Inhibitor, Lung Cancer, Non-Small Cell Lung Cancer, Oncology, Pancreatic Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Sorafenib
4. November 2009 06:47
Exelixis, Inc. announced today that thirteen abstracts related to the company’s development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of XL147 and XL765 will be reported in four poster presentations.
[More]
359e893c-f28b-4929-a4e3-f304e770f6e1|1|1.0
Posted in: Drug Trial News | Medical Condition News
Tags: Biomarker, Biotechnology, Cancer, Carboplatin, Cell, Erlotinib, Glioma, Kinase Inhibitor, Metastasis, Paclitaxel, Temozolomide, Xenograft
3. November 2009 08:00
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.
[More]
76e948f7-1682-41ef-9592-c27fcfaad8a9|0|.0
Posted in: Drug Trial News | Medical Condition News | Pharmaceutical News
Tags: Arthritis, Breast Cancer, Cancer, Cell, Chemotherapy, Kinase Inhibitor, Leukemia, Multiple Myeloma, Myeloid Leukemia, Pathology, Rheumatoid Arthritis
3. November 2009 00:22
ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor.
[More]
23. October 2009 03:57
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
[More]
8cddc26e-36cf-4703-a070-0b4f04381835|0|.0
Posted in: Pharmaceutical News
Tags: Angiogenesis, Antisense, Biochemistry, Cancer, Cell, Chemotherapy, Kinase Inhibitor, Nervous System, Oncology, Pancreatic Cancer, Radiation Therapy, Sexual Dysfunction
22. October 2009 08:07
Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.
[More]
af55a5d4-bed8-46bf-8809-27b9c252f0ae|0|.0
Posted in: Business / Finance
Tags: Anemia, Anti-Inflammatory, Biotechnology, Breast Cancer, Cancer, Cell, Chemotherapy, Chronic Lymphocytic Leukemia, Colorectal Cancer, Kinase Inhibitor, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Myeloid Leukemia, Oncology, Pancreatic Cancer, Placenta, Prostate Cancer, Psoriasis, Ritalin, Small Cell Lung Cancer, Stem Cell, Thalidomide
15. October 2009 01:45
Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.
[More]
14. October 2009 08:12
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.
[More]
15ea8b9f-6512-478a-9741-dd20b7aa7f54|0|.0
Posted in: Business / Finance
Tags: Alzheimer's Disease, Arthritis, Brain, Cancer, Cataract, Cell, Cholesterol, Coronary Artery Disease, Depakote, Diabetes, DNA, Hepatitis C, Immunology, Investment, Kinase Inhibitor, Lung Cancer, Neuroscience, Non-Small Cell Lung Cancer, Nutrition, Oncology, Osteoarthritis, Pfizer, Potassium, Presbyopia, Rheumatoid Arthritis, Schizophrenia, Small Cell Lung Cancer, Stent
Subscribe